It’s welcome news for Alzheimer’s patients and their families: A Food and Drug Administration advisory panel unanimously recommended approval for Eli Lilly & Co.’s treatment donanemab. If given the agency’s green light later this year, it would be the second drug to target amyloid plaques in the brain, which have been associated with the memory-destroying disease.